View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 16, 2020updated 12 Jul 2022 11:57am

Sanofi and Regeneron trial Kevzara to treat severe Covid-19

Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Follow the latest updates of the outbreak on our timeline.

Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.

Kevzara is a fully-human monoclonal antibody, which inhibits the interleukin-6 (IL-6) pathway. The drug is being co-developed by Sanofi and Regeneron.

IL-6 is associated with the overactive inflammatory response in the lungs of severely or critically ill Covid-19 patients.

According to the companies, the trial will be initially performed at medical centres in New York, US.

The multi-centre, double-blind, Phase II / III trial will compare the safety and efficacy of Kevzara in combination with usual supportive care, to placebo and supportive care combination.

With an adaptive design, the trial has two parts, enrolling up to 400 patients.

The first part will enrol severe Covid-19 patients in nearly 16 US sites. It will investigate the drug’s impact on fever and need for supplemental oxygen.

Meanwhile, the second, larger part will monitor longer-term outcomes, such as preventing death and mitigating the need for mechanical ventilation, supplemental oxygen or hospitalisation.

Regeneron Pharmaceuticals co-founder, president and chief scientific officer George Yancopoulos said: “Data from China suggest that the IL-6 pathway may play an important role in the overactive inflammatory response in the lungs of patients with Covid-19.

“Despite this encouraging finding, it’s imperative to conduct a properly designed, randomised trial to understand the true impact. Our trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in Covid-19 patients.”

Last week, Sanofi and Regeneron revealed plans to initiate trials of Kevzara for the treatment of Covid-19 symptoms.

To launch the trial quickly, the companies worked with the US Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA).

Sanofi Research and Development global head John Reed said: “Scientific evidence has emerged to suggest that Kevzara may be a potentially important treatment option for critically-ill COVID-19 patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 receptor inhibition with Kevzara is better than current supportive care alone.”

Reed also notes plans to launch trials outside the US, including most affected regions such as Italy, in the coming weeks.

Separately, Regeneron expanded alliance with BARDA for the development of Covid-19 treatments.

Sanofi vaccines division Sanofi Pasteur is also working with BARDA to assess pre-clinical SARS vaccine candidate for protection against Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena